• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The Vena Tech filter: evaluation of a new inferior vena cava interruption device.

作者信息

Cull D L, Wheeler J R, Gregory R T, Synder S O, Gayle R G, Parent F N

机构信息

Division of Vascular and Transplant Surgery, Eastern Virginia Medical School, Norfolk, Virginia.

出版信息

J Cardiovasc Surg (Torino). 1991 Sep-Oct;32(5):691-6.

PMID:1939334
Abstract

Expanded indications for caval interruption and earlier diagnosis of deep venous thrombosis have resulted in increased use of transvenous caval interruption devices and have intensified the search for the ideal caval filter. The Vena Tech vena cava filter is a percutaneous, transvenous caval interruption device which was recently introduced in the United States. We reviewed our experience with this filter. During the period of September 1989 to July 1990, 41 patients underwent placement of the Vena Tech filter. Indications for filter insertion included deep venous thrombosis with a contraindication to anticogulation (61%), pulmonary embolism while on anticoagulant therapy (29%), and prophylaxis (10%). Insertion was accomplished percutaneously in 40 patients (98%) and via cutdown in one patient. Thirty-nine (95%) were placed from the right internal jugular vein and two (5%) from the right femoral vein. There were no deaths related to filter placement. Incomplete opening of the filter occurred in 8 patients (19%); however, the incidence of deployment problems decreased as our experience increased. Pulmonary embolism after filter placement occurred in one patient (2%). Duplex scan was obtained postoperatively in 15 patients (mean follow-up 120 days). The inferior vena cava was patent in all patients, although nonoccluding thrombus was identified in the filter in one patient. We conclude the Vena Tech filter is an effective device for caval interruption, is easily inserted, and is associated with minimal morbidity.

摘要

相似文献

1
The Vena Tech filter: evaluation of a new inferior vena cava interruption device.
J Cardiovasc Surg (Torino). 1991 Sep-Oct;32(5):691-6.
2
Venous interruption as prophylaxis of pulmonary embolism: vena cava filters.作为肺栓塞预防措施的静脉阻断:腔静脉滤器
Rays. 1996 Jul-Sep;21(3):461-80.
3
Interruption of the inferior vena cava for prevention of pulmonary embolism: transvenous filter devices.下腔静脉阻断预防肺栓塞:经静脉滤器装置
Herz. 1989 Jun;14(3):182-91.
4
Phlegmasia complicating prophylactic percutaneous inferior vena caval interruption: a word of caution.并发预防性经皮腔静脉中断术的血栓形成:需谨慎对待
J Vasc Surg. 1995 Nov;22(5):606-11. doi: 10.1016/s0741-5214(95)70047-1.
5
Inferior vena cava filters. Indications, safety, effectiveness.下腔静脉滤器。适应证、安全性、有效性。
Arch Intern Med. 1992 Oct;152(10):1985-94.
6
[Temporary cava filter: effective prophylaxis of pulmonary embolism in venous thrombosis in the region of the pelvic vascular system and the inferior vena cava?].[临时性腔静脉滤器:对盆腔血管系统和下腔静脉区域静脉血栓形成中肺栓塞的有效预防?]
Rofo. 1995 Dec;163(6):523-6. doi: 10.1055/s-2007-1016039.
7
Therapeutic and prophylactic vena caval interruption for pulmonary embolism: caval and venous insertion site patency.用于肺栓塞的治疗性和预防性腔静脉阻断:腔静脉及静脉插入部位的通畅情况
Ann Vasc Surg. 1993 Nov;7(6):561-8. doi: 10.1007/BF02000151.
8
Percutaneous transvenous caval interruption with the "LGM" filter: early results of a multicenter trial.
Ann Vasc Surg. 1988 Jul;2(3):242-7. doi: 10.1016/S0890-5096(07)60009-0.
9
[Partial interruption of the inferior vena cava using a percutaneous endovenous filter].[经皮静脉内滤器部分阻断下腔静脉]
Arch Mal Coeur Vaiss. 1990 Aug;83(9):1389-96.
10
Early duplex scan evaluation of four vena caval interruption devices.四种腔静脉阻断装置的早期双功超声扫描评估
J Vasc Surg. 1996 Nov;24(5):809-18. doi: 10.1016/s0741-5214(96)70017-4.